CytRx today released a news
release stating it will be presenting at the 16th Annual BIO CEO & Investor
Conference next week at the Waldorf Astoria in New York City. CytRx’s President
and CEO, Steven A. Kriegsman, as well as Vice President of Business
Development, David Haen, will be presenting a corporate update on Monday,
February 10, 2014 at 2:30 pm EST (11:30 am PST).
Among other things, the
company will be covering its expanded 2014 aldoxorubicin development pipeline
after its recent successful $75 million financing. Onlookers are advised to
visit the company’s Investors section, at:
www.cytrx.com/investors/presentations.
CytRx is a biopharmaceutical
research and development company specializing in oncology. CytRx currently is
focused on the clinical development of aldoxorubicin (formerly known as
INNO-206), its improved version of the widely used chemotherapeutic agent
doxorubicin.
For more information, visit:
www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
